



PROTACs

(PROteolysis-TARgeting Chimeras)

Handbook





PROTACs (PROteolysis-TARGETing Chimeras)

PROTAC, short for PROteolysis-TARGETing Chimera, is a heterobifunctional nano molecule containing two different ligands; ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by a linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand^[1].

Once the PROTAC molecule enters the cell, ligand for protein of interest (POI) can specifically bind to the corresponding target protein, while E3 ligase ligand can recruit E3 ligase to form the trimer complex of POI-Linker-E3 ligase, in which E3 ligase mediates ubiquitination on POI by ubiquitin from enzyme E2. POI labeled by ubiquitin is recognized and degraded by the proteasome system. It is not necessary for POI ligand to occupy the binding site for a long time during this progress because of instantaneous ubiquitination after the transient formation of the ternary complex, so PROTAC can be reused many times in cells^[2].




Figure 1. Composition of PROTACs^[1].





Figure 2. PROTAC-mediated degradation of target proteins through the UPS^[2].



PROTAC improves the drugability of protein

Compared with traditional small molecules which need to know the binding site and mechanism of target protein, PROTAC ignores the mechanism of the target protein itself and directly degrades target protein after ubiquitin labeling. In addition, due to its specific mechanism, it requires only a small amount to be effective, often at the nanomolar level. PROTAC is devoid of drug resistance, and has become a solution to the undruggable problem of many tumor intracellular proteins.

Mechanism of Action

1. Ubiquitin activating enzyme E1 activates ubiquitin molecule, then the activated ubiquitin molecule is transferred to ubiquitin conjugating enzyme E2.
2. The complex of ubiquitin ligase E3 and the target protein bridged by the PROTAC molecule binds to E2 following the instructions of E3.
3. The target protein is labeled with ubiquitin because of the increased proximity and collision.
4. Repeating the labeling process above.
5. The target protein labeled with multiple ubiquitinations is eventually recognized and degraded by the proteasome.


Table of Contents

PROTACs


Target Proteins for PROTACs	1
Ligands for Target Proteins for PROTACs.....	2
Ligands for E3 Ligases	4
PROTAC Linkers	6
Building Blocks of Conjugates	8

Target Protein Degraders	9
--------------------------------	---

Technical Service Related to PROTACs	13
--	----



Target Proteins for PROTACs



The protein degraded by the ubiquitin-proteasome pathway include cyclin, fusion-associated protein, cell surface receptor, transcription factor, tumor suppressor, oncogene product, abnormal protein and intracellular denatured protein under stress. In principle, PROTAC can be used for the degradation of all the above proteins.

At present, PROTAC molecules targeting AR, ER, BTK, IKZF1/3, BRD9, Bcl-xl and IRAK4 have entered the stage of clinical development^[3].

Besides PROTAC, there are also other target protein degraders (TPDs) such as LYTAC, AUTAC, ATTEC, which can target proteins from lysosomal pathway^[4].

Figure 3. Ubiquitin-proteasome pathway^[3]






Figure 4. Lysosomal pathway^[4]




Ligands for Target Proteins for PROTACs




Although PROTAC technology is developed to solve the druggability of some proteins, PROTAC molecules nowadays are basically developed based on known protein inhibitors, because the ligand for target protein should be highly selective to avoid off-target toxicity and it costs much to find such an appropriate molecule. For example, the known structure of PROTAC ARV-471 is derived from Tamoxifen, and ARV-766 is from (+)-JQ-1.




MCE can provide you with ligands for the various target proteins to meet your needs for scientific research. We have high-quality products and services. Related popular products are listed below:

Kinases	Epigenetic Factors	Others
<p>HY-10997 Ibrutinib</p> <p>A selective, irreversible Btk inhibitor can be used as a BTK ligand for the synthesis of P131.</p>	<p>HY-13030 (+)-JQ-1</p> <p>A potent, specific, and reversible BET bromodomain inhibitor for the first and second bromodomain (BRD4(1/2)).</p>	<p>HY-114872 SLF</p> <p>A synthetic ligand for FK506-binding protein (FKBP) used in the synthesis of PROTAC.</p>
<p>HY-13001 Quizartinib</p> <p>An orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor.</p>	<p>HY-129939 PROTAC BRD4 ligand-1</p> <p>A potent BET inhibitor, a ligand for target BRD4 protein for PROTACT GNE-987.</p>	<p>HY-A0038 Lasofloxifene (Tartrate)</p> <p>A non-steroidal selective estrogen receptor modulator (SERM).</p>



Kinases 	Epigenetic Factors 	Others 
<p>HY-44432</p> <p>Navitoclax-piperazine</p> <p>A B-cell lymphoma extra large (BCL-XL) inhibitor used in the synthesis of PROTAC DT2216.</p>	<p>HY-130979</p> <p>EED226-COOH</p> <p>An EED226-derived ligand for target protein EED ligand for PROTAC UNC6852 to degrade PRC2.</p>	<p>HY-131388</p> <p>ABM-14</p> <p>A ligand for targeting androgen receptor (AR) for PROTAC ARCC-4.</p>
<p>HY-126534A</p> <p>Abemaciclib metabolite M18 hydrochloride</p> <p>A CDK inhibitor with antitumor activity to design PROTAC CDK4/6 degrader.</p>	<p>HY-107445</p> <p>PROTAC BRD9-binding moiety 1</p> <p>A compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p>	<p>HY-138539</p> <p>CBP/p300 ligand 2</p> <p>A ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective hetero-bifunctional degrader of p300/CBP.</p>
<p>HY-130988</p> <p>Ipatasertib-NH2</p> <p>A ligand for target protein AKT for PROTAC (INY-03-041).</p>	<p>HY-107443</p> <p>I-BET762 carboxylic acid</p> <p>An I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET(BRD4).</p>	<p>HY-131187</p> <p>BMS-1166-N-piperidine-COOH</p> <p>A potent PD-1/PD-L1 interaction inhibitor which antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.</p>
<p>HY-124625</p> <p>BI-4464</p> <p>A highly selective ATP competitive inhibitor of PTK2/FAK.</p>	<p>HY-107451</p> <p>PROTAC BET-binding moiety 1</p> <p>A key intermediate for the synthesis of high-affinity BET inhibitors.</p>	<p>HY-129603</p> <p>SI-109</p> <p>A potent STAT3 SH2 domain inhibitor. A ligand for STAT3 for PROTAC (SD-36).</p>
<p>HY-129967</p> <p>PROTAC IRAK4 ligand-1</p> <p>A synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4).</p>	<p>HY-43723</p> <p>PROTAC BET-binding moiety 2</p> <p>An inhibitor of BET bromodomain.</p>	<p>HY-133073</p> <p>CCR7 Ligand 1</p> <p>An allosteric ligand and antagonist for human CC chemokine receptor 7 (CCR7).</p>



Ligands for E3 Ligases

E3 ligases are usually divided into different families such as RING, HECT, RBR, and each family includes many sub-categories. The discovery of E3 ligases and their ligands promote the continuous enrichment of PROTACs. The ligands of E3 ligases mainly used nowadays focus on three ligases named cereblon (CRBN), von Hippel-Lindau (VHL) and inhibitor of apoptosis protein (IAP). CRBN ligands include thalidomide and other derived immunomodulatory imine drugs (IMiDs). VHL ligands include the long amino acid sequence of HIF-1 α protein and its derivative of peptidomimetic binding part. IAP ligands mainly consist of peptidomimetic antagonists of endogenous components^[5].

In addition, there are some uncommon ligands of E3 ligase, including MDM2, DCAF15, RNF114, DCAF16, KEAP1, and FEM1B.






Figure 5. Common ligands for E3 Ligases^[5].

MCE can provide Ligands for E3 Ligases with various structures and varieties. In addition to common categories, the unusual E3 ligands are also included. Related popular products are listed below:

CRBN	VHL	IAP
<p>HY-10984</p> <p>Pomalidomide</p> <p>A third-generation immunomodulatory agent, acts as molecular glue.</p>	<p>HY-101763A</p> <p>(S,R,S)-AHPC hydrochloride</p> <p>A VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p>	<p>HY-128808</p> <p>cIAP1 ligand 1</p> <p>A LCL161 derivative based IAP ligand which can be connected to the ABL ligand for protein by a linker to form SNIPER.</p>



CRBN	VHL	IAP
<p>HY-23095</p> <p>Thalidomide-5-OH</p> <p>A Thalidomide-based cereblon ligand used in the recruitment of CRBN protein.</p>	<p>HY-125905</p> <p>VH032-cyclopropane-F</p> <p>A VH032-based VHL ligand to form PROTAC 1.</p>	<p>HY-111856</p> <p>LCL161-O-Me</p> <p>A LCL161 derivative based IAP ligand which can be connected to the ABL ligand for protein by a linker to form SNIPER.</p>
<p>HY-W072954</p> <p>Lenalidomide-5-Br</p> <p>A Lenalidomide-based cereblon ligand used in the recruitment of CRBN protein.</p>	<p>HY-120217</p> <p>VH032</p> <p>A VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.</p>	<p>HY-128806</p> <p>E3 ligase Ligand 9</p> <p>A ligand for E3 ubiquitin ligase to form PROTACs or SNIPERs.</p>
<p>HY-101291</p> <p>Iberdomide</p> <p>A cereblon (CRBN) modulator used in the recruitment of CRBN protein.</p>	<p>HY-100947</p> <p>VH-298</p> <p>A highly potent inhibitor of the VHL used in PROTAC technology.</p>	<p>HY-128810</p> <p>E3 ligase Ligand 13</p> <p>A ligand for E3 ubiquitin ligase to form PROTACs.</p>
Others		
<p>HY-128837</p> <p>Nutlin carboxylic acid</p> <p>A Nutlin 3-based MDM2 ligand can be connected to the ligand for protein by a linker to form PROTACs.</p>	<p>HY-131385</p> <p>KB02-COOH</p> <p>A fragment of synthesis of ubiquitin E3 ligase ligand KB02 to form KB02-JQ1 and KB02-SLF.</p>	<p>HY-13650</p> <p>Indisulam</p> <p>A carbonic anhydrase inhibitor with anticancer activity via recruitment to DCAF15.</p>
<p>HY-130842</p> <p>β-Naphthoflavone-CH2-Br</p> <p>An arylhydrocarbon receptor (AhR) ligand used to synthesize β-NF-JQ1.</p>	<p>HY-130269</p> <p>β-Naphthoflavone-CH2-OH</p> <p>A ligand for arylhydrocarbon receptor (AhR) E3 ligase.</p>	<p>HY-125292</p> <p>NV03</p> <p>A potent and selective antagonist of UHRF1- H3K9me3 interaction by binding to UHRF1 tandem tudor domain.</p>



PROTAC Linkers

The linker is a bridge connecting the E3 ligase ligand and target protein ligand. According to the composition, PROTAC Linkers can be divided into PEG, alkyl chain, heteroaryl chain and other fragments. According to the function, the linkers can be divided into ordinary, clickable, and photo-switchable linkers, etc. According to the connecting unit, the linkers can be classified into hydroxyl, amino, mercapto, carboxyl, halogen, alkynyl, and azide, etc.

There is no mature scheme for the selection of PROTAC linkers so linkers are optimized based on structure-activity relationship. It is important to get the modest chain length, because linkers with too short or too long length both decrease the degradation activity^[6].




Figure 6. Effect of Linker length on PROTAC's activity^[6].

MCE can provide PROTAC Linkers with various structures and varieties. In addition to common categories, the unusual E3 ligands are also included. Related popular products are listed below:

Alkyl Motifs

HY-30105

N-Boc-piperazine

Amino/amino connector.

HY-107608


Leukotriene B4

Carboxyl/hydroxyl/double bond connector.

HY-133405

Boc-NH-O-C1-NHS ester

Carboxyl/amino connector.



Alkyl Motifs


<p>HY-W004701</p> <p>Br-C3-methyl ester</p> <p>Halogen/carboxyl connector.</p>	<p>HY-113336B</p> <p>(±)15-HETE</p> <p>Carboxyl/hydroxyl/double bond connector.</p>	<p>HY-W014099</p> <p>Boc-NH-C4-acid</p> <p>Carboxyl/amino connector.</p>
<p>HY-40171</p> <p>NH2-C2-NH-Boc</p> <p>Amino/amino connector.</p>	<p>HY-W018464</p> <p>N-Boc-serinol</p> <p>Hydroxyl/amino connector.</p>	<p>HY-W014831</p> <p>11-Aminoundecanoic acid</p> <p>Amino/carboxyl connector.</p>

PEG Motifs

<p>HY-W008005</p> <p>Amino-PEG4-alcohol</p> <p>Amino/hydroxyl connector</p>	<p>HY-W017772</p> <p>Boc-NH-PEG3</p> <p>Hydroxyl/amino connector</p>	<p>HY-130541</p> <p>Propargyl-PEG2-OH</p> <p>Alkyne /hydroxyl connector</p>
<p>HY-W007713</p> <p>Fmoc-8-amino-3,6-dioxaoctanoic acid</p> <p>Carboxyl/amino connector</p>	<p>HY-42488</p> <p>Hydroxy-PEG3-(CH2)2-Boc</p> <p>Hydroxyl/carboxyl connector</p>	<p>HY-W040246</p> <p>Fmoc-NH-PEG6-CH2CH2COOH</p> <p>Carboxyl/amino connector</p>
<p>HY-W004896</p> <p>Boc-NH-PEG2</p> <p>Hydroxyl/amino connector</p>	<p>HY-22335</p> <p>Amino-PEG4-C2-amine</p> <p>Amino/amino connector</p>	<p>HY-W016735</p> <p>Azido-PEG3-alcohol</p> <p>Azide/hydroxyl connector</p>

Aryl and Heteraryl Motifs

<p>HY-141263</p> <p>Methyltetrazine-acid</p> <p>Carboxyl connector.</p>	<p>HY-W008574</p> <p>TGN-020</p> <p>Amino connector.</p>	<p>HY-113697</p> <p>Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD</p> <p>Mal connector.</p>
--	---	---



Building Blocks of Conjugates

MCE can also provide you with Target Protein Ligand-Linker Conjugates of hot target protein to meet your needs for scientific research. We have high-quality products and services. Related popular products are listed below:

Target Protein Ligand-Linker Conjugates

HY-44148

FAK ligand-Linker Conjugate 1

Extensively used for PROTAC-mediated protein degradation of **FAK**.

HY-141486

Dual PARP EGFR ligand for PROTAC

Used in the synthesis of DP-C-4, which is CRBN-based dual PROTAC for simultaneous degradation of **EGFR** and **PARP**.

HY-139403

MRTX849 ethoxypropanoic acid

Used in the synthesis of PROTAC LC-2 targeting **KRAS^{G12C}**.

MCE also provides E3 Ligase Ligand Linker Conjugates with novel and diverse structures derived from commonly used E3 ligands for rapid conjugation with relevant target protein ligands. Related popular products are listed below:

E3 Ligase Ligand Linker Conjugates

HY-130737

Pomalidomide 4'-alkylC5-acid

A synthesized E3 ligase ligand-linker conjugate based on **cereblon** ligand.

HY-103615

Thalidomide-O-amido-C4-N3

A synthesized E3 ligase ligand-linker conjugate based on **cereblon** ligand.

HY-122725

Lenalidomide-C5-NH2

A synthesized E3 ligase ligand-linker conjugate based on **cereblon** ligand.

HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl

A synthesized E3 ligase ligand-linker conjugate based on **VHL** ligand.

HY-103600


(S,R,S)-AHPC-PEG1-N3

A synthesized E3 ligase ligand-linker conjugate based on **VHL** ligand.

HY-128812

cIAP1 Ligand-Linker Conjugates 11

A synthesized E3 ligase ligand-linker conjugate based on **IAP** ligand.



Target Protein Degraders

PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nano molecule containing two different ligands, ligand for ubiquitin E3 and ligand for the target protein. The two parts are connected by the linker to form a trimer complex, target protein ligand-linker-E3 ligase ligand. The polymer works by targeting protein, using organism's protein-degradation pathway.

Along with PROTAC, there are also other target protein degraders similar to the structure and mechanism of PROTAC like LYTAC, AUTAC and SNIPER.

Lysosome targeting chimera (LYTAC) degrades target proteins via the lysosomal pathway rather than the common proteasome pathway. LYTAC degrades target proteins by binding to the asialoglycoprotein receptor on lysosome through its asialoglycoprotein receptor ligand. Another side of LYTAC is usually an antibody so it can bind to the target protein for degradation^[7].

Autophagy-targeting chimera (AUTAC) degrades target proteins via the lysosomal pathway rather than the common proteasome pathway. One end of AUTAC is the target protein ligand, the other end is a site of K63 ubiquitin modification, and the two parts are connected by a linker. AUTAC induces recognition of LC3 receptors of autophagosomes by K63-linked polyubiquitination and then the Target-AUTAC complex is phagocytosed and transferred into lysosomes for degradation^[8].

Specific and Non-genetic inhibitors of apoptosis protein [IAP]-dependent Protein Erasers (SNIPERs), a class of small-molecule degraders, are designed to induce IAP-mediated ubiquitylation and proteasomal degradation of target proteins^[9].

MCE can provide you with novel and diverse PROTACs, LYTACs, AUTACs and SNIPERs to meet your needs for scientific research. Related popular products are listed below:

PROTAC

HY-112588

dBET6

A highly potent, selective and cell-permeable degrader of **BET** based on PROTAC with antitumor activity.

HY-111556


BSJ-03-123

A potent and novel **CDK6**-selective small-molecule degrader (PROTAC).

HY-129523

PROTAC K-Ras Degradar-1

A potent **K-Ras** degrader based PROTAC, exhibits $\geq 70\%$ degradation efficacy in SW1573 cells.



PROTAC

HY-16954

ARV-825

A **BRD4** degrader based on PROTAC technology which binds to BD1 and BD2 of BRD4.

HY-129602

SD-36

A potent and efficacious PROTAC **STAT3** degrader.

HY-112155

MS4078

An anaplastic lymphoma kinase (**ALK**) PROTAC.

HY-139039

BSJ-4-116

A highly potent and selective **CDK12** degrader.

HY-130615

PROTAC EED degrader-2

A polycomb repressive complex 2 (**PRC2**) inhibitor targeting the EED subunit.

HY-141438

SIM1

A potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all **BET** family members.

LYTAC

HY-139482

tri-GalNAc-COOH

An asialoglycoprotein receptor (ASGPR) ligand that can be used for LYTAC research.

HY-145013

tri-GalNAc-COOH (acetylation)

The acetylated and modified form of tri-GalNAc-COOH. Can be used for the synthesis of LYTAC.

AUTAC

HY-133869

cGMP-HTL

A molecule contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag).

HY-129652


Halo PROTAC 1

A ligand having activity to bind to an intracellular proteins fused with HaloTag and a structure having activity to induce autophagy.

HY-134640

AUTAC4

An AUTAC which can downregulate cytosolic proteins and promote targeted mitochondrial turnover via mitophagy.



SNIPER



HY-111875

SNIPER(BRD)-1

A degrader of both **BRD4**, **clAP1**, **clAP2** and **XIAP**.

HY-111872

SNIPER(ABL)-020

A degrader of **Bcr-Abl** via Dasatinib (ABL inhibitor) and Bestatin (IAP ligand).

HY-111876

SNIPER(TACC3)-1

A degrader targets the **TACC3** protein for degradation based on IAP ligand.

HY-122825

SNIPER(ER)-110

A degrader targets estrogen receptor (**ER**) for degradation based on IAP ligand.

HY-111858

SNIPER(ABL)-050

A PROTAC conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111861

SNIPER(ABL)-024

A PROTAC conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111842

PROTAC CRABP-II Degradar-3

A potent cellular retinoic acid binding protein (**CRABP-II**) degrader based on IAP ligand.

HY-111851

SNIPER(ABL)-049

A PROTAC conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111879

Biotin-BS

A PROTAC contains two different ligands, methyl-bestatin (MeBS) for clAP1 and biotin.

HY-111871

SNIPER(ABL)-033

A PROTAC conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111863

SNIPER(ABL)-047

A PROTAC conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-129619

SNIPER(ER)-87

A PROTAC conjugated to the estrogen receptor α (**ER α**) ligand 4-hydroxytamoxifen by a PEG linker, efficiently degrades the ER α protein.

HY-111854

SNIPER(ABL)-015

A PROTAC conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111874


SNIPER(ABL)-039

A PROTAC conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.

HY-111859


SNIPER(ABL)-058

A PROTAC conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of **BCR-ABL** protein.




Molecular Glues as Target Protein Degraders

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. Molecular glues are a class of small molecule compounds that can induce or stabilize the interaction between proteins. If one of the proteins is ubiquitin ligase, molecular glue can cause another protein to undergo ubiquitin modification and degradation through the proteasome pathway, which is similar to PROTAC^[10].



Autophagosome-tethering compound (ATTEC) degrades target proteins via the lysosomal pathway rather than the common proteasome pathway. ATTEC degrades target proteins by molecular glue mechanism, and its molecular weight is smaller than AUTAC. ATTECs shorten the distance between LC3 receptor and target protein and then the target protein is phagocytosed and transferred into lysosome for degradation^[11].



MCE can provide you with molecular glues and ATTECs to meet your needs for scientific research. Related popular products are listed below:

Molecular Glues

HY-129395

Mezigdomide

A **cereblon** E3 ubiquitin ligase modulating drug, acts as a molecular glue.

HY-130800

Eragidomide


A first-in-class **GSPT1**-selective cereblon E3 ligase modulator, acts as a molecular glue.

ATTEC

HY-130258


LC3-mHTT-IN-AN1

A mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins.




Technical Service Related to PROTACs

MCE can provide one-stop services for the design, synthesis, analysis, purification, optimization, detection and evaluation of PROTAC-related products (Ligands for E3 Ligases, PROTAC Linkers, Ligands for Target Protein for PROTACs, E3 Ligase Ligand-Linker Conjugates, Target Protein Ligand-Linker Conjugates, PROTACs, SNIPERs, PROTAC-Linker Conjugates for PAC). For the target proteins with unknown ligands, we have a variety of compound libraries and virtual screening libraries as the basis to screen protein-related ligands and construct appropriate PROTAC molecules.



Online Consulting:

The corresponding scheme and price for PROTAC shall be determined after evaluation. For further information on service pricing or technical details, please email sales@MedChemExpress.com or contact MCE sales staff directly.



Elements of PROTACs

PROTAC molecules are generally composed of three parts: Ligand for Target Protein, Linker and Ligand for E3 Ligase.

1. Selection of Ligand for E3 Ligase

E3 ligase is a key structure for target protein ubiquitination. Its ligands include many types, among which CRBN (Cereblon), VHL (von Hippel-Lindau), IAP and MDM2 are now frequently used. Ligands of CRBN with good drug-likeness are generally preferred, followed by VHL and IAP derived from endogenous ligand peptides. Consideration should also be given to the abundance of the corresponding E3 ligase in the cell where the specific target protein is located and the physical and chemical parameters of the final PROTAC.

2. Selection of Linker

Linkers are molecules that connect ligand for E3 ligase and ligand for the target protein. The properties of linkers have a great influence on the membrane permeability, efficacy and metabolic distribution of PROTAC. The ideal linker length should be able to maintain the lowest binding entropy of the two proteins without affecting their binding in space. There are also studies on multiple connectors and photoswitchable linkers.

3. Selection of Ligand for Target Protein

As the guiding group of PROTAC, the target protein ligand is responsible for capturing the target protein, which requires high coordination ability and selectivity. In practical applications, existing inhibitors and activators of proteins can be used as ligand candidates, while proteins without related molecule reports can be searched for ligands by high-throughput screening (HTS) and Virtual Screening. It is not necessary for ligands to be inhibitor or agonist, but it should be highly specific to the target protein.

Our Advantages:



Quick Delivery

Delivered for using at the earliest time, reducing the intermediate procedures



Price Concessions

High cost performance and competitive prices



Product Reports

Provide real and reliable experimental data related to PROTACs



In strict Confidence

Sign a confidentiality agreement with MCE for absolute security



Professional Consultation

Professional technicians will answer and solve your doubts in time.



Abundant Species

3,000+ PROTAC products for worldwide customers



Specialized Capacity

Professional synthesis ability and rich experience




Cutting-Edge Technology

Continuous technological innovation for design and synthesis service

References:


- [1] Cell Biochem Funct.2019;37(1):21-30.
- [2] Expert Opin Ther Pat. 2021, 31(1):1-24.
- [3] Nat Med.2020;6(10):1073-1081.
- [4] Cells. 2020 Sep 22;9(9):2140.
- [5] Front Chem.2021 Jul 5;9:707317.
- [6] J Med Chem.2021;64(12):8042-8052.
- [7] Trends Pharmacol Sci.2020;41(7):464-474.
- [8] Mol Cell.2019;76(5):797-810.e10.
- [9] Chem Pharm Bull (Tokyo).2019 Mar 1;67(3):203-209.
- [10] Cell.2021;184(1):3-9.
- [11] Nature.2019;575(7781):203-209.





MCE

Master of Bioactive Molecules



Inhibitors • **Screening Libraries** • **Proteins**

www.MedChemExpress.com

MedChemExpress USA

Tel: 609-228-6898

E-mail: sales@MedChemExpress.com

Fax: 609-228-5909

Tech Support: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

For research use only.

We do not sell to patients.

MedChemExpress Europe

Tel: +4686500910

E-mail: eu.sales@MedChemExpress.com

Address: Bergkällavägen 37C 192 79 Sollentuna SWEDEN

Master of
Bioactive Molecules

www.MedChemExpress.com